PIRAMAL PHARMA Q4 NUMBERS

Piramal Pharma Q4 Results: Net profit slides 75% YoY to Rs 50 crore

On like-to-like financials, the CDMO business that contributes 57 per cent of revenues, declined 8 per cent YoY to Rs 2164 crore. The complex hospital generics business grew 28 per cent due to strong demand for the inhalation anesthesia portfolio. The consumer health business sales rose 5 per cent to Rs 206 crores driven by sustained marketing and brand building efforts.